

FACT SHEET

COMPANY PROFILE

Biotest is a specialist in innovative haematology, clinical immunology and intensive care medicine. Biotest develops, manufactures and markets plasma proteins and biotherapeutic drugs. Our value chain extends from pre-clinical and clinical development to worldwide marketing and distribution. Biotest manufactures immunoglobulins, clotting factors and albumins which derive from human blood plasma. Biotest currently employs more than 2,400 people worldwide.

The most important raw material for our pharmaceuticals is human blood plasma, which we process into effective and highly purified drugs in one of our world leading fractionation facilities in Europe. These medications are used to treat life-threatening diseases such as blood coagulation disorders (haemophilia), severe infections and immune system disorders.

MANAGEMENT BOARD



Peter Janssen
 Chairman of the Board of Management

Ainhua Mendizabal Zubiaga
 Chief Financial Officer

Dr. Jörg Schüttrumpf
 Chief Scientific Officer

SUPERVISORY BOARD

> **Dr. Bernhard Ehmer**
 Chairman

> **Raimon Grifols Roura**


> **David Bell**

> **Uta Kemmerich-Keil**

> **Jürgen Heilmann**

> **Dirk Schuck**


SHARE CHART OF ORDINARY SHARES



KEY DATA OF ORDINARY SHARES

ISIN	DE0005227201
WKN	522 720
Share type	Ordinary
Bloomberg Code	BIO@GR
Reuters Code	BIOG_p.DE
Ticker	BIO
Branch	Pharma
Index	Prime All Share
Segment	Prime Standard
Last Dividend	EUR 0.04 for 2023
No. of shares	19.785.726
Market Cap	EUR 827.04 mn
52 week high	EUR 44.00
52 week low	EUR 39.60
Stock exchanges	Regulated market in Frankfurt (Prime Standard); Open Market in Berlin, Dusseldorf, Hamburg/Hanover, Munich, Stuttgart, Tradegate

SHARE CHART OF PREFERENCE SHARES



KEY DATA OF PREFERENCE SHARES

ISIN	DE0005227235
WKN	522 723
Share type	Preference
Bloomberg Code	BIO@GR
Reuters Code	BIOG_p.DE
Ticker	BIO3
Branch	Pharma
Index	Prime All Share
Segment	Prime Standard
Last Dividend	EUR 0.04 for 2023
No. of shares	19.785.726
Market Cap	EUR 508.49 mn
52 week high	EUR 33.20
52 week low	EUR 22.80
Stock exchanges	Regulated market in Frankfurt (Prime Standard); Open Market in Berlin, Dusseldorf, Hamburg/Hanover, Munich, Stuttgart, Tradegate

FACT SHEET

ANNUAL FIGURES

	2017 ¹⁾	2018 ¹⁾	2019	2020	2021	2022	2023
in EUR millions							
Sales	378.1	400.3	419.1	484.2	515.6	516.1	684.6
EBITDA	13.0	35.2	30.5	28.3	-16.0	19.2	179.4
EBIT	-9.3	10.6	-1.2	-1.3	-47.1	-16.6	143.5
Profit before tax	-26.0	-6.0	-1.3	-30.0	-62.6	-30.8	106.3
Net profit	-16.4	-12.9	-4.7	-31.4	-63.4	-31.7	127.0
Balance Sheet Total	978.5	1,042.3	1,108.4	1,131.3	1,104.2	1,203.0	1,410.9
Shareholders' equity	347.8	495.0	476.9	441.6	380.4	371.1	498.9
Dividend in EUR^{2) 3)}							
Ordinary shares	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Preference shares	0.04	0.04	0.04	0.04	0.04	0.00	0.04
Staff⁴⁾	1,659	1,663	1,837	1,928	1,967	2,227	2,426

All figures according to IFRS

¹⁾ Continuing operations

²⁾ On 15 July 2015 Biotest AG reorganises stock exchange listing due to share split with the ratio one to three. By implementing the capital increase and the share split the existing shareholder structure does not change. The share capital of Biotest AG amounted to € 33,767,639.04 before the capital increase and was divided into 6,595,242 ordinary shares and 6,595,242 preference shares without voting rights. Thus, one ordinary or preference share had a proportional amount of the share capital of € 2.56. After the implementation of the capital increase from capital funds by € 5,803,812.96 to € 39,571,452.00 without issuing new shares and the share split, each former holder of one existing ordinary or preference share now holds three ordinary or preference shares with a proportional amount of the share capital of € 1.00. After capital increase and share split the amount of ordinary shares and preference share amounts to each 19,785,726 shares. The previous year's figures have been adjusted to the new amount of shares.

³⁾ 2021: proposed at AGM on May 05, 2022

⁴⁾ in FTEs (Full time equivalents)

SHAREHOLDER STRUCTURE

Ordinary Shares:

Release according to § 33 Abs. 1 WpHG:

96.20%	Grifols S.A.*
0.13%	Polygon Global Partners LLP
0.07%	UBS Group AG

*: On 2 May 2022, Grifols, S.A. published in accordance with sec. 23 para. 2 sentence 1 WpÜG, that Grifols, S.A. acquired further 0.94 % of the voting rights in Biotest AG. Therefore, Grifols, S.A. holds 97.14 % of the voting right in Biotest AG.

Preference Shares:

100.00%	Free float
---------	------------

FINANCIAL CALENDAR

Nov 05, 2024 Publication quarterly statement (call-date Q3)

Biotest AG

Biotest AG
 Landsteinerstraße 5
 63303 Dreieich
 Deutschland

Tel.: 0 61 03 - 8 01-0
 Fax: 0 61 03 - 8 01-150
 ir@biotest.com
 www.biotest.com

Contact Investor Relations

Dr. Monika Bauman (Buttkereit)

Head of Investor Relations Biotest AG
 Landsteinerstraße 5
 D-63303 Dreieich
 Phone: +49 (0) 61 03 - 801 4406
 Fax: +49 (0) 61 03 - 801 347
 E-Mail: ir@biotest.com